Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies

Gerber, 2005, Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies, Cancer Res, 65, 671 Zondor, 2004, Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies, Ann Pharmacother, 38, 1258, 10.1345/aph.1D470 Hicklin, 2005, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, J Clin Oncol, 23, 1011, 10.1200/JCO.2005.06.081 Rosen, 2002, Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers, Cancer Control, 9, 36, 10.1177/107327480200902S05 Herbst, 2005, Angiogenesis and lung cancer: Prognostic and therapeutic implications, J Clin Oncol, 23, 3243, 10.1200/JCO.2005.18.853 Mod, 2005, Bevacizumab in combination chemotherapy forcolorectal and othercancers, Am J Health Syst Pharm, 62, 1021, 10.1093/ajhp/62.10.1021 Midgley, 2005, Bevacizumab-current status and future directions, Ann Oncol, 16, 999, 10.1093/annonc/mdi208 Akagi, 1998, Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I, Cancer Res, 58, 4008 Nasu, 1999, Blood flow influences vascular growth during tumour angiogenesis, Br J Cancer, 79, 780, 10.1038/sj.bjc.6690125 Folkman, 1995, Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis, N Engl J Med, 333, 1757, 10.1056/NEJM199512283332608 Gasparini, 2005, Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions, J Clin Oncol, 23, 1295, 10.1200/JCO.2005.10.022 Kabbinavar, 2005, Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer, J Clin Oncol, 23, 3706, 10.1200/JCO.2005.00.232 Rosen, 2005, VEGF-targeted therapy: Therapeutic potential and recent advances, Oncologist, 10, 382, 10.1634/theoncologist.10-6-382 Augustin, 2003, Translating angiogenesis research into the clinic: The challenges ahead, Br J Radiol, 76, S3, 10.1259/bjr/68078705 Avastin, 2004 Wang, 2004, Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro, Angiogenesis, 7, 335, 10.1007/s10456-004-8272-2 Kabbinavar, 2005, Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results ofa randomized phase II trial, J Clin Oncol, 23, 3697, 10.1200/JCO.2005.05.112 Jain, 2001, Normalizing tumorvasculature with anti-angiogenic therapy: A new paradigm for combination therapy, Nat Med, 7, 987, 10.1038/nm0901-987 2006 Melnyk, 1999, Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model, J Urol, 161, 960, 10.1016/S0022-5347(01)61829-9 Mesiano, 1998, Role ofvascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization, Am J Pathol, 153, 1249, 10.1016/S0002-9440(10)65669-6 Chen, 2004, Expanding the clinical development of bevacizumab, Oncologist, 9, 27, 10.1634/theoncologist.9-suppl_1-27 Borgstrom, 1999, Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin, Anticancer Res, 19, 4203 Brower, 2003, Evidence of efficacy: Researchers investigating markers for angiogenesis inhi bitors, J Natl Cancer Inst, 95, 1425, 10.1093/jnci/95.19.1425 Jubb, 2006, Impact of vascular endothelial growth factor-A expression, thrombospondin 2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer, J Clin Oncol, 24, 217, 10.1200/JCO.2005.01.5388 Nguyen, 1997, Angiogenic factors as tumor markers, Invest New Drugs, 15, 29, 10.1023/A:1005766511385 Miller, 2005, Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer, J Clin Oncol, 23, 792, 10.1200/JCO.2005.05.098 Hillan, 2003, The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC) Dowlati, 2006, Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC) Gordon, 2001, Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer, J Clin Oncol., 19, 843, 10.1200/JCO.2001.19.3.843 Lin, 1999, Preclinical pharmacokinetics, interspecies scaling, and tissue distribu tion of a humanized monoclonal antibody against vascular endothelial growth factor, J Pharmacol Exp Ther., 288, 371 2006 Schueller, 2006, Influence of bevacizumab on the plasma disposition of CPT 11 and its metabolites in advanced colorectal cancer patients Weiss, 2004 Park, 2003, Measuring response in solid tumors: Comparison of RECIST and WHO re sponse criteria, Jpn J Clin Oncol., 33, 533, 10.1093/jjco/hyg093 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors, J Natl Cancer Inst., 92, 205, 10.1093/jnci/92.3.205 de Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol., 18, 2938, 10.1200/JCO.2000.18.16.2938 Douillard, 2000, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial, Lancet, 355, 1041, 10.1016/S0140-6736(00)02034-1 Goldberg, 2004, Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer, Cancer Chemother Pharmacol., 54, S57 Saltz, 2000, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer, N Engl J Med., 343, 905, 10.1056/NEJM200009283431302 Grothey, 2004, Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment, J Clin Oncol., 22, 1209, 10.1200/JCO.2004.11.037 Meyerhardt, 2005, Systemic therapy for colorectal cancer, N Engl J Med., 352, 476, 10.1056/NEJMra040958 Venook, 2005, Critical evaluation of current treatments in metastatic colorectal cancer, Oncologist, 10, 250, 10.1634/theoncologist.10-4-250 Tournigand, 2004, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study, J Clin Oncol., 22, 229, 10.1200/JCO.2004.05.113 Fernando, 2004, Targeted therapy of colorectal cancer: Clinical experience with bevacizumab, Oncologist, 9, 11, 10.1634/theoncologist.9-suppl_1-11 1998, Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer, Clin Oncol., 16, 301, 10.1200/JCO.1998.16.1.301 Kelly, 2005, Systemic therapy for metastatic colorectal cancer: Current options, current evidence, J Clin Oncol., 23, 4553, 10.1200/JCO.2005.17.749 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med., 350, 2335, 10.1056/NEJMoa032691 Hurwitz, 2005, Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for firstline metastatic colorectal cancer, J Clin Oncol., 23, 3502, 10.1200/JCO.2005.10.017 Kabbinavar, 2003, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol., 21, 60, 10.1200/JCO.2003.10.066 Petrelli, 1989, The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial, J Clin Oncol., 7, 1419, 10.1200/JCO.1989.7.10.1419 Giantonio, 2005, High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 Hochster, 2005, Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/ fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cencer (mCRC): TREE 1 & 2 Studies Hochster, 2005, Bevacizumab (B) with oxaliplatin (O)based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): Preliminary results of the randomized “TREE-2” trial Hochster, 2006, Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis ofthe TREE-Study Spigel, 2006, Phase II study of FOLFOX4, bevacizumab, and erlotinib as first-line therapy in patients with advanced colorectal cancer Fernando, 2005, A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer Saltz, 2005, Randomized phase II trial of cetuximab/ bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer Diaz-Rubio, 2004, New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers, Oncologist, 9, 282, 10.1634/theoncologist.9-3-282 Hedrick, 2006, Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the U.S. (BRiTE) Kozloff, 2006, Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE) Schneider, 2005, Angiogenesis of breast cancer, J Clin Oncol., 23, 1782, 10.1200/JCO.2005.12.017 Burstein, 2002, Phase II trial of anti-VEGFantibody bevacizumab in combination with vi norelbine for refractory advanced breast cancer Ramaswamy, 2003, CTEP-sponsored phase II trial of bevacizumab (Avastin) in combi nation with docetaxel (Taxotere) in metastatic breast cancer Cobleigh, 2003, A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer, Sernin Oncol, 30, 117, 10.1053/j.seminoncol.2003.08.013 Miller, 2005, E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer Brady, 1997, Reliability and validity of the Functional Assessment ofCancer Therapy Breast quality-of-life instrument, J Clin Oncol., 15, 974, 10.1200/JCO.1997.15.3.974 Rugo, 2004, Bevacizumab in the treatment of breast cancer: Rationale and current data, Oncologist, 9, 43, 10.1634/theoncologist.9-suppl_1-43 Overmoyer, 2004, Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer Herbst, 2004, Non-small cell lung cancer and antiangiogenic therapy: What can be expected of bevacizumab?, Oncologist, 9, 19, 10.1634/theoncologist.9-suppl_1-19 Ushijima, 2001, High vascularity in the peripheral region of non-small cell lung can cer tissue is associated with tumor progression, Lung Cancer, 34, 233, 10.1016/S0169-5002(01)00246-X Passalidou, 2002, Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas, Br J Cancer., 86, 244, 10.1038/sj.bjc.6600015 Di Maio, 2005, Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: A pooled analysis of three randomised trials, Lancet Oncol., 6, 669, 10.1016/S1470-2045(05)70255-2 Sobrero, 2005, Bevacizumab plus fluorouracil: The value of being part of a developing story, J Clin Oncol., 23, 3660, 10.1200/JCO.2005.11.941 Herbst, 2005, Phase I/II trial evaluating the anti-vascular endothelial growth fac tor monoclonal antibody bevacizumab in combination with the HER-1/ epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer, J Clin Oncol., 23, 2544, 10.1200/JCO.2005.02.477 Johnson, 2004, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol., 22, 2184, 10.1200/JCO.2004.11.022 Sandler, 2005, Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC#704865) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599 Hainsworth, 2005, Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib, J Clin Oncol, 23, 7889, 10.1200/JCO.2005.01.8234 Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med., 349, 427, 10.1056/NEJMoa021491 van Spronsen, 2005, Novel treatment strategies in clear-cell metastatic renal cell carcinoma, Anticancer Drugs, 16, 709, 10.1097/01.cad.0000167901.58877.a3 Turner, 2002, Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation, Cancer Res., 62, 2957 Beeram, 2004, Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma (RCC) Bukowski, 2006, Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC) Jemal, 2004, Cancer statistics, 2004, CA Cancer J Clin, 54, 8, 10.3322/canjclin.54.1.8 Kindler, 2005, Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer, J Clin Oncol., 23, 8033, 10.1200/JCO.2005.01.9661 Itakura, 2000, Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer, Int J Cancer., 85, 27, 10.1002/(SICI)1097-0215(20000101)85:1<27::AID-IJC5>3.0.CO;2-8 Baker, 2002, Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer, Cancer Res., 62, 1996 Bruns, 2002, Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice, Int J Cancer., 102, 101, 10.1002/ijc.10681 Burris, 1997, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial, J Clin Oncol., 15, 2403, 10.1200/JCO.1997.15.6.2403 D'Adamo, 2005, Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas, J Clin Oncol., 23, 7135, 10.1200/JCO.2005.16.139 Picus, 2003, The use of bevacizumab (B) with docetaxel (D) and extramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006 Zhu, 2005, A phase II study ofgemcitabine, oxaliplatin in combination with be vacizumab (GEMOX-B) in patients with hepatocellular carcinoma Santoro, 1995, Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, J Clin Oncol., 13, 1537, 10.1200/JCO.1995.13.7.1537 Giles, 2001, The vascular endothelial growth factor (VEGF) signaling pathway: A therapeutic target in patients with hematologic malignancies, Oncologist, 6, 32, 10.1634/theoncologist.6-suppl_5-32 Sane, 2004, Angiogenic growth factors and hypertension, Angiogenesis, 7, 193, 10.1007/s10456-004-2699-3 Pande, 2006, Bevacizumab (BV) induced hypertension (HT): A manageable toxicity 2006 Ostendorf, 1999, VEGF165 mediates glomerular endothelial repair, J Clin Invest., 104, 913, 10.1172/JCI6740 Ratner, 2004, Genentech discloses safety concerns over Avastin, Nat Biotechnol., 22, 1198, 10.1038/nbt1004-1198 Rowinsky, 2004, Safety, pharmacokinetics, and activity ofABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer, J Clin Oncol., 22, 3003, 10.1200/JCO.2004.11.061 Saltz, 2006, Simplification of bevacizumab (bev) administration: Do we need 90, 60, or even 30 minute infusion times? Berenson, 2006, A cancer drug shows promise, at a price that many can't pay, New York Times, A1, C2 Mayer, 2004, Two steps forward in the treatment of colorectal cancer, N Engl J Med., 350, 2406, 10.1056/NEJMe048098